Pfizer signs deal with Allogene to develop cancer cell therapy

(Reuters) – Pfizer Inc said on Tuesday it signed an agreement with Allogene Therapeutics, a company formed by a consortium in which the drugmaker will hold a 25 percent stake, to further develop its allogenic CAR T cell therapy.

Source: Reuters Medical News

Leave a Reply

Your email address will not be published. Required fields are marked *